XML 19 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Stockholders' Equity
(3) Stockholders' Equity
Dividends
On April 12, 2023, our board of directors declared a quarterly dividend of $0.35 per share of common stock to be paid in cash on May 25, 2023 to shareholders of record at the close of business on April 27, 2023.
The following table presents the cash dividends either paid previously or declared by our board of directors for future payment on a per share basis:
20232022
First quarter$0.35 $0.31 
Second quarter$0.35 $0.31 
Third quarter$0.31 
Fourth quarter$0.31 
Total$0.70 $1.24 
Stock Options
The following tables summarize the details of options granted under our stock option plans that were outstanding as of March 31, 2023, and the assumptions used to value those grants. All such grants were effective at the close of business on the date of grant.
 Options
Granted
Option Exercise
Price
Closing Stock Price on Date
of Grant
March 31, 2023
Date of GrantOptions
Outstanding
Options
Exercisable
January 3, 20231,071,943 $48.00 $47.400 1,062,367 70,562 
January 3, 2022713,438 $62.00 $61.980 666,921 53,355 
January 4, 2021741,510 $48.00 $47.650 654,243 244,108 
January 2, 2020902,263 $38.00 $37.230 744,467 382,024 
January 2, 20191,316,924 $26.00 $25.705 900,545 559,781 
January 2, 20181,087,936 $27.50 $27.270 658,540 527,626 
January 3, 20171,529,578 $23.50 $23.475 651,325 547,059 
April 19, 20161,690,880 $23.00 $22.870 478,231 356,861 
April 21, 20151,786,440 $21.00 $20.630 322,855 247,151 
April 22, 20141,910,000 $28.00 $25.265 30,298 30,298 
Total12,750,912 6,169,792 3,018,825 

Date of GrantRisk-free
Interest Rate
Expected Life of
Option in Years
Expected
Dividend
Yield
Expected
Stock
Volatility
Estimated Fair
Value of Stock
Option
January 3, 20234.0 %5.002.6 %29.58 %$11.62 
January 3, 20221.3 %5.001.7 %28.52 %$13.68 
January 4, 20210.4 %5.002.0 %29.17 %$9.57 
January 2, 20201.7 %5.002.4 %25.70 %$6.81 
January 2, 20192.5 %5.002.9 %23.96 %$4.40 
January 2, 20182.2 %5.002.3 %23.45 %$5.02 
January 3, 20171.9 %5.002.6 %24.49 %$4.20 
April 19, 20161.3 %5.002.6 %26.34 %$4.09 
April 21, 20151.3 %5.002.7 %26.84 %$3.68 
April 22, 20141.8 %5.002.0 %28.55 %$4.79 
All of the options in the tables above vest and become exercisable over a period of up to eight years. Generally, each option will terminate approximately 10 years after the grant date.
The fair value of each share-based option is estimated on the date of grant using a Black-Scholes valuation method that uses the assumptions listed above. The risk-free interest rate is based on the U.S. Treasury rate over the expected life of the option at the time of grant. The expected life is the average length of time over which we expect the employee groups will exercise their options, net of forfeitures, which is based on historical experience with similar grants. The dividend yield is estimated over the expected life of the option based on our current dividend payout, historical dividends paid, and expected future cash dividends. Expected stock volatilities are based on the movement of our stock price over the most recent historical period equivalent to the expected life of the option.
Compensation expense equal to the grant date fair value is recognized for all of these awards over the vesting period. The stock-based compensation expense for the three-month periods ended March 31, 2023 and 2022 was $1.9 and $1.5, respectively. Unrecognized stock-based compensation expense related to outstanding unvested stock options as of March 31, 2023 was $22.3 and is expected to be recognized over a weighted average period of 4.67 years. Any future changes in estimated forfeitures will impact this amount.
Earnings Per Share
The following tables present a reconciliation of the denominators used in the computation of basic and diluted earnings per share and a summary of the options to purchase shares of common stock which were excluded from the diluted earnings per share calculation because they were anti-dilutive:
 Three-month Period
Reconciliation20232022
Basic weighted average shares outstanding570,928,848 575,559,161 
Weighted shares assumed upon exercise of stock options1,703,741 2,059,645 
Diluted weighted average shares outstanding572,632,589 577,618,806 
 Three-month Period
Summary of Anti-dilutive Options Excluded20232022
Options to purchase shares of common stock2,269,908 930,401 
Weighted average exercise prices of options$52.17 58.40 
Any dilutive impact summarized above related to periods when the average market price of our stock exceeded the exercise price of the potentially dilutive stock options then outstanding.